Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients With Diabetes Mellitus

X
Trial Profile

A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients With Diabetes Mellitus

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucagon (Primary) ; Glucagon
  • Indications Hypoglycaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 25 Sep 2020 Results pooled post hoc analyses of two randomised, cross-over studies (NCT03421379, NCT03339453) assessing efficacy, pharmacodynamics, and safety of nasal glucagon compared to injectable glucagon in reversing insulin induced hypoglycaemia in Caucasian and Japanese adults with type 1 diabetes or type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes.
    • 25 Sep 2020 Results (n=214) of pooled post hoc analyses of 3 randomised, cross-over studies (NCT03421379, NCT03339453, NCT01994746) assessing efficacy and safety of nasal glucagon compared to 1 mg intramuscular injectable glucagon in reversing insulin-induced hypoglycaemia in adults with type 1 diabetes or type 2 diabetes, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 06 Dec 2019 Results of post hoc analysis presented at the 2019 Congress of the International Diabetes Federation.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top